In vivo binding and antitumor activity of Ch14.18 - PubMed (original) (raw)

In vivo binding and antitumor activity of Ch14.18

K Kendra et al. J Immunother. 1999 Sep.

Abstract

The melanoma reactive chimeric 14.18 (ch14.18) antibody can mediate enhanced in vitro lysis of human M-21 melanoma cells. This study analyzes the antitumor effects and the in vivo binding of ch14.18 antibody with M-21 melanoma cells in severe combined immunodeficiency (SCID) mice. Outgrowth of tumors was prevented in 6/6 animals by the simultaneous subcutaneous injection of peripheral blood mononuclear cells (PBMC) [3 x 10(6) cells (2 animals); 10 x 10(6) cells (2 animals); and 30 x 10(6) cells (2 animals)], with 0.5 mg ch14.18, 1,500 U interleukin 2 (IL-2), and 10(6) M-21 cells. In contrast, 7 of 7 control mice that received M-21 cells alone, 7 of 7 mice that received M-21 cells and ch14.18, and 5 of 6 mice that received M-21 cells plus PBMC plus IL-2, grew subcutaneous tumors. The in vivo localization of ch14.18 was then evaluated in an intraperitoneal (i.p.) tumor model, where 0.3 cm melanoma nodules develop within 3 weeks after the i.p. administration of M-21 cells. Flow cytometric and immunohistochemical analysis revealed the GD2 antigen present throughout the tumor nodule. Intraperitoneal administration of 0.01, 0.1, or 1.0 mg of ch14.18 to SCID mice previously engrafted i.p. with M-21 cells resulted in detectable ch14.18 binding to tumor cells in vivo within 10 hours of antibody administration. Ch14.18 penetration was limited to approximately 20 cell layers, demonstrating that ch14.18 has limited access to some cells in large tumor nodules. This study demonstrates that the addition of ch14.18 to IL-2 and human effector cells can result in significant antitumor activity by preventing the establishment of tumor nodules. These results suggest that clinical testing of IL-2 plus ch14.18 might be most effective if used in the setting of microscopic residual disease. Therapies that enhance ch14.18 penetration into tumor nodules should be evaluated with ch14.18 for patients with advanced melanoma.

PubMed Disclaimer

Cited by

Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma.
Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, Smith M, Anderson B, Villablanca JG, Matthay KK, Shimada H, Grupp SA, Seeger R, Reynolds CP, Buxton A, Reisfeld RA, Gillies SD, Cohn SL, Maris JM, Sondel PM; Children's Oncology Group. Yu AL, et al. N Engl J Med. 2010 Sep 30;363(14):1324-34. doi: 10.1056/NEJMoa0911123. N Engl J Med. 2010. PMID: 20879881 Free PMC article. Clinical Trial.
NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer Immunotherapy.
Wang W, Erbe AK, Hank JA, Morris ZS, Sondel PM. Wang W, et al. Front Immunol. 2015 Jul 27;6:368. doi: 10.3389/fimmu.2015.00368. eCollection 2015. Front Immunol. 2015. PMID: 26284063 Free PMC article. Review.
Antigen specificity can be irrelevant to immunocytokine efficacy and biodistribution.
Tzeng A, Kwan BH, Opel CF, Navaratna T, Wittrup KD. Tzeng A, et al. Proc Natl Acad Sci U S A. 2015 Mar 17;112(11):3320-5. doi: 10.1073/pnas.1416159112. Epub 2015 Mar 2. Proc Natl Acad Sci U S A. 2015. PMID: 25733854 Free PMC article.
IgA antibody immunotherapy targeting GD2 is effective in preclinical neuroblastoma models.
Stip MC, Evers M, Nederend M, Chan C, Reiding KR, Damen MJ, Heck AJR, Koustoulidou S, Ramakers R, Krijger GC, de Roos R, Souteyrand E, Cornel AM, Dierselhuis MP, Jansen M, de Boer M, Valerius T, van Tetering G, Leusen JHW, Meyer-Wentrup F. Stip MC, et al. J Immunother Cancer. 2023 Jul;11(7):e006948. doi: 10.1136/jitc-2023-006948. J Immunother Cancer. 2023. PMID: 37479484 Free PMC article.
The Advances and Challenges of NK Cell-Based Cancer Immunotherapy.
Kang S, Gao X, Zhang L, Yang E, Li Y, Yu L. Kang S, et al. Curr Oncol. 2021 Feb 26;28(2):1077-1093. doi: 10.3390/curroncol28020105. Curr Oncol. 2021. PMID: 33652996 Free PMC article. Review.

In vivo binding and antitumor activity of Ch14.18 - PubMed (original) (raw)